July 6, 2017

PharmaCyte Biotech Releases Presentation to Oncologists and Interviews from 2017 ASCO Meeting Event

LAGUNA HILLS, Calif., July 06, 2017 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the release of 3 videos from the company's presentation and discussion with oncologists who attended this year's annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The videos consist of a presentation made to a group of oncologists who have expressed an interest in participating in PharmaCyte's pivotal clinical trial in locally advanced, inoperable and non-metastatic pancreatic cancer (LAPC). They also include interviews with PharmaCyte's Chief Operating Officer, Dr. Gerald W. Crabtree, and the Chairman of PharmaCyte's Medical and Scientific Advisory Board, Dr. Matthias Löhr.

The videos can be viewed at: www.PharmaCyte.com/Media

The Chief Executive Officer of PharmaCyte, Kenneth L. Waggoner, commented, "We hope our shareholders and the investment community will find these videos informative and useful. They explain how our platform technology for pancreatic cancer works and how we intend to use that technology to treat LAPC. They also illustrate where we are in the life-cycle of our development of an effective cellular therapy for pancreatic cancer with no treatment related side effects."

About PharmaCyte Biotech

PharmaCyte Biotech is a clinical stage biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as "Cell-in-a-Box®." This technology will be used as a platform upon which cellular therapies for several types of cancer and diabetes are being developed.

PharmaCyte's therapy for pancreatic cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or "cancer-killing" form. These encapsulated cells are implanted in the blood supply as close to the patient's cancerous tumor as possible. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through the encapsulated cells, they act as a "bio-artificial liver" and activate the chemotherapy drug at the site of the cancer. This "targeted chemotherapy" has proven effective and safe to use in past clinical trials and results in no treatment related side effects.

PharmaCyte's cellular therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as a "bio-artificial pancreas" for purposes of insulin production.

Safe Harbor

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement because of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements due to the impact of numerous risk factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

More information about PharmaCyte Biotech can be found atwww.PharmaCyte.com. Information may also be obtained by contacting PharmaCyte's Investor Relations Department.

Contact:

Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com

PHARMACYTE BIOTECH

Source: PharmaCyte Biotech, Inc.